Evidence map›Paper›PMID 28923906›Full record

Trial reportCirculation2017

Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus.

Kristina Striepe, Agnes Jumar, Christian Ott, Marina V Karg, Markus P Schneider, Dennis Kannenkeril, Roland E Schmieder

3 registry-linked trialsAbstract readLetterRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Circulation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT02471963. Cited by 78 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02471963 phase3completed

Randomized, Double-blind, Placebo Controlled, Crossover Clinical Study to Analyse the Effect of Empagliflozin on Macrovascular and Microvascular Circulation and on Endothelium Function

Ran2014Enrolled74Registered outcomes4Posted comparisons0ConditionsDiabetes Mellitus Type 2Armsempagliflozin, Placebo
Open the trial in the graph
NCT02752113 phase3completed

ELMI - Prospective, Randomized, Controlled, Parallel-arm Study to Assess the Effects of the Combined Therapy of Empagliflozin and Linagliptin Compared to Metformin and Insulin Glargine on Renal and Vascular Changes in Type 2 Diabetes

Ran2016Enrolled101Registered outcomes4Posted comparisons0ConditionsDiabetes Mellitus Type 2ArmsEmpagliflozin and Linagliptin, Metformin and Insulin sc
Open the trial in the graph
NCT03128528 phase2completed

Randomized, Double-blind, Placebo Controlled, Parallel-group, Prospective Clinical Study to Analyse the Effect of Empagliflozin on Reduction of Tissue Sodium Content in Patients With Chronic Heart Failure

Ran2017Enrolled84Registered outcomes14Posted comparisons0ConditionsChronic Heart FailureArmsempagliflozin 10mg, Placebo Oral Tablet
Open the trial in the graph
3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Review

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kristina StriepeFrom Department of Nephrology and Hypertension, University Hospital Erlangen, Bavaria, Germany.
Agnes JumarFrom Department of Nephrology and Hypertension, University Hospital Erlangen, Bavaria, Germany.
Christian OttFrom Department of Nephrology and Hypertension, University Hospital Erlangen, Bavaria, Germany.
Marina V KargFrom Department of Nephrology and Hypertension, University Hospital Erlangen, Bavaria, Germany.
Markus P SchneiderFrom Department of Nephrology and Hypertension, University Hospital Erlangen, Bavaria, Germany.
Dennis KannenkerilFrom Department of Nephrology and Hypertension, University Hospital Erlangen, Bavaria, Germany.
Roland E SchmiederFrom Department of Nephrology and Hypertension, University Hospital Erlangen, Bavaria, Germany. roland.schmieder@uk-erlangen.de roland.schmieder@fau.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Administration, OralAdolescentAdultAgedBenzhydryl CompoundsCardiovascular DiseasesCross-Over StudiesDiabetes Mellitus, Type 2Double-Blind MethodDrug Administration ScheduleFemaleGermanyGlucosidesHemodynamicsHumansMaleBenzhydryl CompoundsempagliflozinGlucosidesSodium-Glucose Transporter 2 Inhibitorscentral systolic pressureempagliflozinpulse wave analysisSGLT-2 inhibitortype 2 diabetes mellitus

Identifiers

PMID28923906

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.